Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by fouremmon Apr 28, 2015 10:51am
223 Views
Post# 23671525

RE:RE:RE:RE:RE:RE:RE:RE:RE:bloomberg article....... ouch to those whom we know....

RE:RE:RE:RE:RE:RE:RE:RE:RE:bloomberg article....... ouch to those whom we know....Hi poc, Yes RVX owes $68 million dollars in 2 years and change.  I can think of a number of ways that can be dealt with by a management team that has even a little bit of experience.  I don't however think for a second that Eastern is motivated to take RVX out but if it actually came to that management could sell the company cheaply, pay the debt and distribute the balance to shareholders including Eastern all of whom would probably be getting far less than the company is worth.  Something, in that sceario, would be better than nothing for management, NGN, H.S. and all the rest of us.  Again, I don't think that is the way it will go.  More likely share float or term extension depending on market conditions and as long as RVX is still a going concern, which I think it will be in that time frame if it has not been sold.

I may be a "soso thinker" but you should try doing a least a TINY bit of thinking in amongst all your laughing and ridiculous fear mongering
Bullboard Posts